Respiratory Drug Delivery 2012 - In Review
Respiratory Drug Delivery 2012 was held at the JW Marriott Desert Resort & Spa, Phoenix, Arizona during May 13-17, 2012. Over 600 registrants from all over the world gathered in Arizona to review the latest science and clinical learning from a diverse cadre of presenters. Approximately 54% of the attendees were from the USA and Canada, while 35% were from Europe and 8% Australia, India, China and South America. Pharmaceutical industry participants made up the bulk of the audience (38% Research & Development, 20% Sales, Marketing and Business professionals, 10% Management, and 8% Engineers, Process / Packaging, QbD) but we saw increased academic (12%) and regulatory (5%) participation in what continues to emerge as a thriving field of scientific and clinical endeavor.
The organizers of the meeting and Virginia Commonwealth University were honored to award the 2012 “Charles G. Thiel Award", endowed at VCU by 3M Drug Delivery Systems, for outstanding research and discovery in respiratory drug delivery to Andy Clark who pioneered inhaler developments through scientific understanding and publication across disciplines (physics, chemistry, biology and medicine). Andy helped develop some of the most innovative aerosol products of the last two decades including Pulmozyme, the first inhaled protein, Exubera, the first inhaled systemic protein and TOBI Podhaler, the first inhaled dry powder antibiotic, tobramycin.
Professor Ian Hall, from the University of Nottingham in the United Kingdom, presented the plenary lecture on the topic Genetics and Personalized Medicines in Respiratory Disease: How Good is the Evidence? Subsequent sessions addressed advances in asthma, targeting for improved topical effects, respiratory vaccines, emerging markets for inhaled products, debating the dissolution boundaries for inhalation products and science and technology of powder inhalers. Several sessions focused on the importance of the use of inhalers by patients, the impact of adherence on outcomes and patient focused models and devices. To (b) or (j) - That is the Question was a lively session concerned with the drug approval approaches in the US. This session was audio recorded and will be available online later this summer. As part of RDD's effort to disseminate information from around the world, the presentation by Mr Maozhong Li, Deputy Director of the SFDA was simultaneously translated from Chinese to English with both languages included in the Proceedings.
RDD 2012 provided an excellent opportunity for scientific and commercial networking during the meeting’s signature Scientific Poster and Technology Exhibition. Companies, universities and others presented 108 scientific posters with selected contributions shared with the entire audience during Posters on the Podium. The Technology Exhibition brought together representatives of the world's pharmaceutical companies active in the pulmonary and nasal areas with their suppliers and service providers in a relaxed atmosphere.
In response to feedback from previous meetings, delegates at RDD 2012 were able to choose between receiving peer reviewed abstracts of all podium and poster presentations either in printed or electronic form via a specially designed conference website; with WiFi access sponsored by RDD Online.
The organizers thank all our presenters, exhibitors, and sponsors for their contribution to RDD 2012, and we look forward to meeting you all again at Respiratory Drug Delivery Europe 2013 at the Intercontinental Hotel, in Berlin Germany May 21-24, 2013.